Page 1

october 2014


Vol 7, No 4

COMPLIMENTARY CE Faculty Perspectives™: Latest Treatment Advances for Individualized Care of Breast Cancer

see page 18

Breast Cancer

Cancer Center Profile

Cancer Hospital of New Jersey at Robert Wood Johnson University Hospital

Relation Between Stomatitis and Clinical Outcomes of Everolimus Treatment Examined by Trial Investigators Caroline Helwick


Some of the oncology pharmacy team members at the Cancer Hospital of New Jersey (left to right): Jigisha Patel, PharmD; Jon Lalli, PharmD, BCOP; and Isabel Caratenuto, PharmD.


he Cancer Hospital of New Jersey at Robert Wood Johnson University Hospital (RWJUH) is the flagship hospital of the Rutgers Cancer Institute of New Jersey. It is the only Comprehensive Cancer Center in New Jersey designated by the National Cancer Institute. The partnership between RWJUH and Rutgers Cancer Institute of New Jersey allows patients to receive care from research physicians in a state-of-the-art environment. Continued on page 6

Conference News

Highlights From the American Society for Radiation Oncology 2014 Annual Meeting Alice Goodman


he annual meeting of the American Society for Radiation Oncology (ASTRO) took place in San Francisco, California, on September 14-17, 2014. The meeting draws more than 11,000 attendees, bringing together clinicians, scientists, and researchers from all oncology disciplines. ASTRO highlights how technology and biology advance the field of radiation oncology and improve out-

comes and quality of life for patients. As ASTRO’s needs statement for the annual meeting points out, nearly twothirds of the estimated 1.6 million people who will be diagnosed with cancer this year will receive radiation therapy—this makes it imperative that all members of the multidisciplinary team be aware of best practices. Below are summaries of some highlights from the meeting. Continued on page 9

n patients receiving everolimus in clinical trials, stomatitis frequently occurred in the initial weeks of treatment, but this did not compromise clinical outcomes, according to Hope S. Rugo, MD, Professor of Medicine and Director of Breast Oncology and Clinical Trials at the University of California San Francisco Helen Diller Family Comprehensive Cancer Center. In fact, there was some indication that the occurrence of stomatitis was actually predictive of greater treatment benefit, she noted at the American Society of Clinical Oncology’s 2014 Breast Cancer Symposium.

“In this retrospective analysis, stomatitis appeared to be associated with longer progression-free survival [PFS]” in most of the trials, Rugo indicated, though she cautioned that this was an unplanned analysis. “In many patients with stomatitis, we reduced or held doses. We can’t say the outcome is better in patients who got stomatitis, but it’s certainly not worse. It tells us that patients who get stomatitis, even though we hold or reduce doses, have at least the same PFS, and in some patients, stomatitis may be a marker [of prognosis],” Rugo said. Continued on page 5


The Path to Oncology Pharmacy Eric Urnoski, 2015 PharmD candidate


y philosophy has always been to cherish each educational opportunity or experience not only for professional development but also for personal growth. Adhering to this principle, I took advantage of every available chance to learn and grow as a pharmacy student. While in high school, I had the opportunity to transition from a grocery

store cashier to a pharmacy technician after waiting for a position within the company to become available. In addition, I was briefly employed at a specialty mail order pharmacy to help diversify my work experiences and explore the many work settings pharmacy has to offer. Over the next several years, I was able to use these experiences to develop my Continued on page 8

i n s i d e The Whole Patient . . . . . . . . . 12 Renal Cancer. . . . . . . . . . . . . . . 28 The Psychosocial Effects of Chemotherapy-Induced Alopecia

Side Effects Management. . . . . . . . . . . . . . . . . . 15 Generic Docetaxel Increases Neutropenia Risk and Healthcare Costs Vaginal DHEA May Improve Sexual Function in Women With Breast/ Gynecologic Cancer

©2014 Green Hill Healthcare Communications, LLC

Highest Response Rate to Date in mRCC With Pazopanib as Third-Line VEGF Inhibitor


Melanoma . . . . . . . . . . . . . . . . . . . . Potential New Approach to Treat Melanoma Combination of BRAF and MEK Inhibitors Improves Survival in Advanced Melanoma

Profile for The Oncology Pharmacist

TOP Oct 2014 | Vol 7 | No 4  

The Onology Pharmacist, October 2014, Volume 7, Number 4

TOP Oct 2014 | Vol 7 | No 4  

The Onology Pharmacist, October 2014, Volume 7, Number 4